Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2019-2023
About this market
COPD is a chronic non-communicable, lifestyle-related disease, which progresses continuously in the absence of medical intervention. There are several lifestyle-related factors such as smoking, exposure to biomass fuel, and air pollution, which increase the risk of developing COPD. In addition to tobacco smoke, there are other factors such as occupational exposure, outdoor pollution. exposure to second-hand or passive smoking. smoke from the burning of biomass, respiratory infections, poor nutritional status, chronic asthma, impaired lung growth, poor socio-economic status. and dietary factors, which lead directly or indirectly to COPD. Apart from lifestyle factors, there are factors such as old age and presence of rare genetic disorders. which contribute to the rising prevalence of COPD. Technavio’s analysts have predicted that the chronic obstructive pulmonary disease (COPD) drugs market will register a CAGR of almost 4% by 2023.
Strong pipeline and new drug approvals
The pipeline for the treatment of COPD includes several drug combinations, which can provide a wide range of therapeutic benefits. These drug combinations are presently in the late stages of development, with some expected to be launched in the market during the forecast period. These molecules combine the properties of drugs from different classes and have diversified therapeutic mechanisms of action and hence are expected to change the course of COPD treatment.
Low diagnosis rates for COPD
There is a lack of knowledge and awareness about COPD especially in the developing countries due to which primary care practitioners (PCPs) and other healthcare providers delay or incorrectly diagnose COPD. Another major factor contributing to the poor diagnosis of COPD is the diagnostic confusion between COPD and asthma. Thus, poor or incorrect diagnosis is a major challenge as it prevents people with COPD from getting a proper diagnosis which, in turn, has a negative impact on market growth.
For the detailed list of factors that will drive and challenge the growth of the chronic obstructive pulmonary disease (COPD) drugs market during the 2019-2023, view our report.
The chronic obstructive pulmonary disease (COPD) drugs market appears to be moderately concentrated and with the presence of few companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook